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 During the infection of cells by animal viruses, membrane permeability is modified 
at two different steps of the virus life cycle (Carrasco, 1995) (Figure 1). Initially, when the 
virion enters cells, a number of different-sized molecules are able to co-enter the 
cytoplasm with the virus particles (Fernandez-Puentes and Carrasco, 1980; Otero and 
Carrasco, 1987). Membrane potential is reversibly destroyed, being restored several 
minutes later. Endosomes are involved in the co-entry process, since inhibitors of the 
proton ATPase block early permeabilization even with viruses that do not require 
endosomal function. A chemiosmotic model has been advanced to explain the molecular 
basis of early membrane modification by virus particles (Carrasco, 1994). The viral 
molecules involved are components of virions: glycoproteins when enveloped particles are 
analyzed or, still unidentified, domains of the structural proteins in the case of naked 
viruses. Attachment of the particle to the cell surface receptor does not alter membrane 
permeability by itself. Inhibitors that hamper virus decapsidation, still allowing virus 
attachment to the cell surface, block early membrane permeabilization (Almela et al., 
1991). 
 At late times of infection, when there is active translation of late viral mRNAs, the 
plasma membrane becomes permeable to small molecules and ions (Carrasco, 1978) 
(Figure 1). Different viral molecules may be responsible for this late enhancement of 
membrane permeability, including viroporins (Gonzalez and Carrasco, 2003), 
glycoproteins and even proteases (Chang et al., 1999; Blanco et al., 2003). This chapter is 
devoted to reviewing some characteristics of membrane permeabilization by viral proteins. 
In addition, the methodology used to assay enhanced permeability in animal cells is 
described. Finally, the design of selective viral inhibitors based on the modification of 
cellular membranes during virus entry or at late times of infection is also discussed. 
 
2. MEASURING ALTERATIONS IN MEMBRANE PERMEABILITY 
2.1. The hygromycin B test 
 A number of hydrophilic molecules, including some antibiotics, poorly permeate 
through cellular membranes (Contreras et al., 1978; Lacal et al., 1980). This is the case of 
hygromycin B, anthelmycin, blasticidin S, destomycin A, gougerotin and edein complex. 
The aminoglycoside antibiotic hygromycin B (MW 527) is produced by Streptomyces 
hygroscopicus. This hydrophilic molecule is an efficient inhibitor of protein synthesis in cell-
free systems but interferes very poorly with translation in intact cells. However, the 
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modification of the plasma membrane by viruses or by other means leads to a rapid 
blockade of translation (Carrasco, 1995). Concentrations of the antibiotic ranging from 
about 0.1-1 mM are added to the culture medium and protein synthesis is estimated by 
incubation with radioactive methionine for 1 hr (See figure 2) (Gonzalez and Carrasco, 
2001). In addition to its simplicity, the hygromycin B test has a number of advantages for 
assaying changes in membrane permeability. One is its great sensitivity, and another is 
that this test measures membrane modifications only in cells that are metabolically active. 
Moreover, in cultures where some cells are uninfected, hygromycin B would only enter 
virus-infected cells that are synthesizing proteins. The hygromycin B test has been applied 
with success to prokaryotic (Lama and Carrasco, 1992) and eukaryotic cells, including 
yeast (Barco and Carrasco, 1995;Barco and Carrasco, 1998) and mammalian cells (Gatti 
et al., 1998; Gonzalez and Carrasco, 2001). 
2.2. Entry of macromolecules into virus-infected cells 
 Alpha-sarcin is a protein of 150 amino acid residues, which is produced by 
Aspergillus giganteus (Oka et al., 1990). This protein inhibits translation by modifying 
ribosomes in an enzymatic manner. Thus, a molecule of alpha-sarcin is able to inactivate a 
great number of ribosomes by hydrolysis of the A4324-G4325 phosphodiester bond in the 
28S rRNA (Chan et al., 1983). This toxin does not enter mammalian cells because it does 
not attach to the cell surface and is therefore unable to cross the plasma membrane. 
However, alpha-sarcin efficiently interferes with protein synthesis in cell-free systems or in 
cells where the permeability barrier has been destroyed (Fernandez-Puentes and 
Carrasco, 1980). Alpha-sarcin co-enters cells in conjunction with virus particles, and is 
liberated to the cytoplasm (Otero and Carrasco, 1987; Liprandi et al., 1997). In this 
manner, this toxin irreversibly blocks translation several minutes after virus entry. The 
molecular basis of the co-entry of macromolecules with virus particles has been analyzed 
in detail elsewhere (Carrasco, 1994; Carrasco, 1995). Apart from alpha-sarcin, a number 
of proteins that interfere with translation, many of them of plant origin, have been 
described (Fernandez-Puentes and Carrasco, 1980; Lee et al., 1990). The release of all 
these toxins into cells is enhanced by virus particles. Not only proteins, but also other 
macromolecules, including nucleic acids efficiently co-enter with virus particles (Cotten et 
al., 1992). However, none of these macromolecules passes into cells at late times of 
infection. 
2.3. Other assays to test the entry or exit of molecules from virus-infected cells 
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Apart from the use of translation inhibitors that do not easily permeate into intact 
cells, a number of assays can be employed to assess modifications in membrane 
permeability. Amongst these assays we can list the following: 
2.3.1. Entry or exit of radioactive molecules.  
Cells are preloaded with radioactive uridine and the exit of nucleotides can be 
monitored after induction of viroporin expression (Gonzalez and Carrasco, 1998). Unlike 
with most amino acids, the pool of uridine nucleotides is abundant in the cell interior, thus 
providing a convenient and sensitive assay for monitoring the exit of molecules from cells. 
Other tests use radioactive glucose derivatives (e.g., 2-deoxyglucose), which cannot be 
metabolized and accumulate in cells. The analysis of the release of radioactive 
compounds that are not actively transported into cells leads to the failure to measure 
enhanced membrane permeability. 
2.3.2. Entry of ONPG and dyes 
Entry of o-nitrophenyl-ß-D-galactopyranoside (ONPG) into the bacterial cells can 
be determined very simply. This ß-galactosidase substrate can be incubated with bacterial 
cells and production of the resulting compound can be followed by determining the 
absorbance at 420 nm (Lama and Carrasco, 1992). There are a number of non-vital dyes 
employed to characterize cell mortality. It should be noted that the entry of these 
compounds in fact determines a modification in cell membranes, which in some cases 
does not directly correlate with cell death. Trypan blue is a dye widely used for monitoring 
enhanced membrane permeability. However, this assay is not very sensitive. In addition, 
trypan blue staining does not discriminate between metabolically active or dead cells, as 
the hygromycin B tests does. Another assay employs the polyamine neurobiotin that 
needs specific connexin channels to enter mammalian cells (Elfgang et al., 1995). 
Permeabilization of cell membrane increases uptake of this cationic molecule. Internalized 
neurobiotin can be detected in paraformaldehyde-fixed cells, by fluorescence microscopy, 
using fluorescein isothiocyanate-conjugated streptavidin (Gonzalez and Carrasco, 1998). 
2.3.3. Entry of propidium iodide 
Propidium iodide (PI) is a DNA-intercalating compound that does not enter intact 
cells. However, those cells that exhibit increased membrane permeability are able to take 
up PI, which can be assayed by cell fluorometric analysis (Arroyo et al., 1995). 
2.3.4. Release of cellular enzymes to the culture medium 
The appearance in the culture medium of cellular enzymes is a clear indicator of 
cell mortality. This is the case for lactic dehydrogenase and bacterial ß-galactosidase, 
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present outside the cells (Sanderson et al., 1996). Commercial kits to measure this 
enzymatic activity are available. The release of cellular proteins to the medium occurs at 
very late times of viral infection, when cells have already died. This alteration takes place 
at much later times after hygromycin B entry can be detected (Blanco et al., 2003). 
 
3. VIRAL PROTEINS THAT MODIFY PERMEABILITY 
3.1. Viroporins 
Viroporins are small proteins encoded by viruses that contain a stretch of 
hydrophobic amino acids (Gonzalez and Carrasco, 2003). Typically, viroporins are 
comprised of some 60-120 amino acids. The hydrophobic domain is able to form an 
amphipathic α-helix. The insertion of these proteins into membranes followed by their 
oligomerization creates a hydrophilic pore. The architecture of this channel is such that the 
hydrophobic amino acid residues face the phospholipid bilayer while the hydrophilic 
residues form part of the pore. In addition to this domain, there are other features of 
viroporin structure, including a second hydrophobic region in some viroporins that also 
interacts with membranes. This second interaction may further disturb the organization of 
the lipid bilayer. These proteins may also contain a stretch of basic amino acids that acts 
in a detergent-like fashion. All these structural features contribute to membrane 
destabilization. More recently, another domain has been described in some glycoproteins 
and also viroporins that has the capacity to interact with membranes. This domain is rich in 
aromatic amino acids and is usually inserted at the interface of the phospholipid bilayer 
(Suarez et al., 2000; Sanz et al., 2003). This type of interaction also leads to membrane 
destabilization, further enhancing membrane permeability. 
A number of viroporins from different viruses that infect eukaryotic cells have been 
reported. This group of proteins includes picornavirus 2B and 3A, alphavirus 6K, retrovirus 
Vpu, paramixovirus SH, orthomixovirus M2, reovirus p10, flavivirus p7, phycodnavirus Kcv, 
coronavirus E and rhabdovirus alpha 10p. A recent review devoted to viroporins discusses 
the structure and function of a number of proteins of this group (Gonzalez and Carrasco, 
2003), and so the details of each particular viroporin will not be reviewed in this chapter. 
The main activity of viroporins is to create pores at biological membranes to permit 
the passage of ions and small molecules. The cloning and individual expression of 
viroporin genes has allowed their effects in bacterial and animal cells to be analyzed. 
Thus, the expression of this type of viral gene enhances the permeation of ions and 
several hydrophilic molecules in or out of cells (Carrasco, 1995). In addition, the purified 
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viroporin molecules open pores in model membranes, providing a system that is amenable 
to biophysical analysis (Fischer and Sansom, 2002). The pore size created by viroporins 
allows the diffusion of different molecules with a molecular weight below about 1000 Da. 
The main step affected in animal viruses containing a deleted viroporin gene is the 
assembly and exit of virions from the infected cells (Klimkait et al., 1990; Liljestrom et al., 
1991; Loewy et al., 1995; Betakova et al., 2000; Watanabe et al., 2001; Kuo and Masters, 
2003). These genes are not essential for virus replication in culture cells, but the plaque 
size is much smaller in viroporin-defective viruses. Notably, virus entry and gene 
expression in viroporin-deleted viruses occur as in their wild-type counterparts. An aspect 
of viroporin function at the molecular level that is still not understood is the link between 
pore activity and virus budding. 
3.2. Viral glycoproteins that modify membrane permeability  
In addition to small hydrophobic viral proteins, there are other virus products that 
promote membrane permeabilization. This occurs with a number of virus glycoproteins 
that are known to increase cell membrane permeability such as the human 
immunodeficiency virus gp41 (Chernomordik et al., 1994; Arroyo et al., 1995), the Ebola 
virus GP protein (Yang et al., 2000), the cytomegalovirus US9 protein (Maidji et al., 1996), 
the Vaccinia virus A38L protein (Sanderson et al., 1996), rotavirus VP7 and NS4 proteins 
(Newton et al., 1997; Charpilienne et al., 1997), the hepatitis C virus E1 protein 
(Ciccaglione et al., 1998), and the alphavirus E1 protein (Nyfeler et al., 2001; Wengler et 
al., 2003). 
The architecture of some viral glycoproteins is such that upon oligomerization, the 
transmembrane (TM) domains may form a physical pore. In principle, two different regions 
of a viral fusion glycoprotein could form pores. One such region contains the fusion 
peptide that would create a pore in the cell membranes upon insertion (Skehel and Wiley, 
1998), while the TM domain would form a pore in the virion membrane (Wild et al., 1994). 
Moreover, sequences adjacent to the transmembrane region could have motifs designed 
to destabilize membrane structure (Suarez et al., 2000). Entry of enveloped animal viruses 
leads to early membrane permeabilization, which is mediated by the formation of the two 
pores (fusion and TM) formed by viral fusion glycoproteins. This early permeabilization 
induced during the entry of virions requires conformational changes of the fusion 
glycoproteins. By contrast, after virus replication newly synthesized glycoproteins may 
affect membrane permeability when they reach the plasma membrane (Figure 3). This 
modification is achieved only by the TM domain, while the fusion peptide does not 
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participate in this late modification. In viruses that lack the typical viroporin, its function 
could be replaced by these pore-forming glycoproteins, while for other viruses viroporin 
activity may be redundant (Bour and Strebel, 1996). In the latter case, pore formation may 
be generated by viral glycoproteins and viroporins (Figure 3). We would like to propose the 
possibility that pore-forming glycoproteins play a key role mainly during virus entry and in 
some cases also during virus budding, while viroporins come into action when viruses 
need to exit the cell. 
Early membrane permeabilization is always carried out by a virion component. In 
the case of enveloped viruses this early event is executed by a structural glycoprotein, 
which is coupled to the fusion process. An understanding of fusion at the molecular level 
also requires an explanation of the phenomenon of early membrane permeabilization. We 
have advanced the idea that viral glycoproteins involved in membrane fusion participate in 
the dissipation of the chemiosmotic gradient, thus providing the energy to push the 
nucleocapsid and neighboring macromolecules to the cell interior (Carrasco, 1994; Irurzun 
et al., 1997). Fusion glycoproteins do not simply serve to bridge the cellular and the viral 
membrane, but instead are designed to open pores in both membranes. This pore-
opening activity may be necessary to lower membrane potential and to dissipate ionic 
gradients. Several chapters of this book are devoted to the detailed description of the 
structure and function of these glycoproteins, so we will focus our attention on viral 
glycoproteins that permeabilize membranes when individually expressed in cells. These 
membrane active proteins may exhibit this activity late on in the virus life cycle. 
3.2.1. Rotavirus glycoprotein 
 Rotavirus infection provokes a number of alterations in cellular membranes during 
infection (del Castillo et al., 1991). Amongst these alterations, there is an increase in the 
concentration of cytoplasmic calcium, (Michelangeli et al., 1991). Several rotavirus 
proteins exhibit membrane-destabilizing activity. The enterotoxin NSP4 induces alterations 
in membrane permeability (Tian et al., 1994). The individual expression of the non-
structural glycoprotein NSP4 has the ability to increase the concentration of cytoplasmic 
calcium. This increase may be mediated by activation of phospholipase C activity (Dong et 
al., 1997). 
 Rotavirus particles induce the co-entry of protein toxins into cells (Cuadras et al., 
1997). At least two structural components possess the ability to permeabilize cells, 
including VP5 protein and VP7 glycoprotein (Charpilienne et al., 1997; Irurzun et al., 
1997). 
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3.2.2. The HIV-1 gp41 
Infection of lymphocytic human cells by HIV-1 enhances membrane permeability to 
ions and several compounds (Voss et al., 1996; Gatti et al., 1998). There are at least three 
different HIV-encoded proteins responsible for these alterations: Vpu protein, the retroviral 
protease and the fusion glycoprotein gp41. Apart from the fusion peptide, there are two 
regions of gp41 that exhibit membrane permeability; one is located at the carboxy terminus 
(Arroyo et al., 1995; Comardelle et al., 1997) and another corresponds to the membrane-
spanning domain. (Arroyo et al., 1995). The C terminus of gp41 includes two 20 to 30 
residues, which may form cationic amphipathic α-helices, designated as lentivirus lytic 
peptides 1 and 2 (LLP-1 and LLP2). Synthetic LLP-1 peptide forms pores in planar 
phospholipid bilayers (Chernomordik et al., 1994), permeabilizes HIV-1 virions to 
deoxyribonucleoside triphosphates (Zhang et al., 1996) and induces alterations in ion 
permeability of Xenopus oocytes (Comardelle et al., 1997).  
3.2.3. Other viral glycoproteins 
Inducible expression of the hepatitis C virus E1 glycoprotein increases membrane 
permeability in bacterial cells. The ability of E1 to modify membrane permeability has been 
mapped to the carboxy terminus of the protein (Ciccaglione et al., 1998; Ciccaglione et al., 
2001). Similar permeabilization was found with E. coli cells that synthesize Semliki forest 
virus E1 glycoprotein after exposure to low pH (Nyfeler et al., 2001). Finally, 
overexpression of Vaccinia virus A38L glycoprotein produces changes in the morphology, 
permeability and adhesion of mammalian cells. The potential capacity of A38L protein to 
form pores at the plasma membrane promotes the entry of calcium ions and propidium 
iodide and the release of lactic dehydrogenase into the culture medium (Sanderson et al., 
1996). 
 
4. MEMBRANE PERMEABILIZATION AND DRUG DESIGN 
4.1. Antibiotics and toxins that selectively enter virus-infected cells 
Different approaches have been envisaged for the design of compounds that 
interfere with virus replication based on modifications in membrane permeability. One such 
approach makes use of inhibitors of cellular or viral functions that do not permeate easily 
into intact animal cells. Notably these agents selectively enter into virus-infected cells 
(Carrasco, 1978; Benedetto et al., 1980). Most of the inhibitors used thus far interfere with 
protein synthesis, although compounds that affect other functions could also be employed. 
Entry of these agents leads to the inhibition of translation specifically in virus-infected cells, 
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leading to a profound inhibition of virus growth (Contreras et al., 1978; Carrasco, 1995; 
Gatti et al., 1998). Although this approach discriminates well between uninfected or virus-
infected cells in culture, the high toxicity of the agents thus far assayed has hampered its 
use in whole animals. Perhaps future searches for less toxic compounds would make this 
approach amenable to application in therapy. In fact, some of the plant toxins that co-enter 
with virus particles have been described as being antiviral agents (Lee et al., 1990). Even 
compounds such as hygromycin B, which has been used in the veterinary field as an 
antibacterial agent, could also be used as an antiviral compound for rotavirus infections 
(Liprandi et al., 1997). 
4.2. Viroporin inhibitors 
The paradigm of an inhibitor of a viral ion channel is amantadine (Hay, 1992) 
(Figure 4). This compound has been used as an anti-influenza agent in humans (De 
Clercq, 2001). The target of amantadine is the influenza-encoded protein M2. Residues 
27, 30, 31 and 34 of M2 determine the amantadine sensitivity of this ion channel. A 
drawback of amantadine is the high doses necessary to affect influenza. The search for 
more effective compounds may provide a more efficacious treatment for this illness. 
Compounds that interfere with the functioning of other viroporins have also been 
described. This is the case of amiloride derivatives that block HIV-1 Vpu activity (Ewart et 
al., 2002). In this manner the production of infectious HIV-1 is reduced in the presence of 
this agent. Recently, long alkyl-chain iminosugar derivatives have been found to interfere 
with the function of the hepatitis C virus p7 protein as an ion channel (Griffin et al., 2003; 
Pavlovic et al., 2003). These compounds exhibited antiviral activity with bovine viral 
diarrhea virus, which is closely related to the hepatitis C virus. (Durantel et al., 2001)  
4.3. Antiviral agents that interfere with viral glycoproteins 
Much effort has been concentrated recently on the development of antiviral agents 
that inhibit the fusion step of HIV. Binding of HIV gp120 to the CD4 receptor is followed by 
further interaction of this viral glycoprotein with the coreceptor molecules CXCR4 and 
CCR5. After this initial interaction, the conformation of the ectodomain of the 
transmembrane glycoprotein gp41 is profoundly modified. Exposure of the fusion peptide 
at the amino terminus of gp41 triggers its insertion into the target cellular membrane, 
leading to the fusion of the viral and the cellular plasma membranes. All these steps have 
been used as targets for anti-HIV therapy (Cooley and Lewin, 2003). As regards the fusion 
step, a variety of peptide mimetic inhibitors has been developed. The pioneering work on 
peptide T20 has demonstrated that this compound is a potent inhibitor of gp41-induced 
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membrane fusion. T20 exhibits antiviral activity in HIV-infected patients. The detailed 
mechanism of action of T20 at the molecular level is known. This peptide is homologous 
with 36 amino acids within the C terminal heptad repeat region (HR2) of HIV-1 gp41. T20 
competitively binds to HR1 and interferes with the formation of the six helix HR1-HR2 
bundle complex necessary for membrane fusion. At present there are a great number of 
peptides that interfere with binding of gp120 or with gp41-induced membrane fusion and 
that have been tested for their anti-HIV activity and clinical efficacy. In this regard, T1249 
is one of the second generation of HR-2 peptide mimetic inhibitors that consists of 39 
amino acids. PRO 542 is a soluble CD4 receptor (CD4-IgG2) that binds to and neutralizes 
gp120 before virus binding occurs. SCH-C is an oxime-piperidine compound that is a 
coreceptor antagonist. This small molecule acts as an inhibitor of CCR5. MD3100 is a 
non-peptidic low molecular weight bicyclam compound that prevents interactions between 
CXCR4 and gp120, blocking signal transduction from CXCR4. Future research in this field 
will provide us with additional antiviral compounds to add to the anti-HIV armory. 
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Figure 1: Panel A. Schematic representation of early membrane permeability. The 
different steps of virus attachment, entry and fusion events are shown. The protein toxin 
alpha-sarcin co-enters endosomes in conjunction with animal virus particles . The fusion of 
the viral membrane with the endosome membrane induces the release of alpha-sarcin to 
the cytoplasm. Panel B: Permeabilization of the plasma membrane at late times of 
infection. The figure depicts the entry of the low molecular weight translation inhibitor 
hygromycin B through pores created at the plasma membrane. Alpha-sarcin is unable to 






Figure 2: Entry of hygromycin B into BHK cells promoted by the expression of HIV-1 Vpu. 
Control BHK cells (left), cells infected with Sindbis virus lacking the 6K gene (SV(-6K)); 
(center) or with (SV(-6K)) containing the HIV-1 vpu gene (SV(-6K)+Vpu) (right) were 
treated or not with 0.5 mM hygromycin B for 10 min and protein synthesis was assayed by 
extended incubation with [35S] Met/Cys for 1 hr. The labeled proteins were analyzed by 







Figure 3: Participation of pore formation by viral glycoproteins and viroporins in 
membrane permeability. Early membrane permeabilization is coupled to the fusion activity 
of the corresponding viral glycoprotein. This fusion glycoprotein may create two pores. 
One is located at the target cell membrane and the other is formed by the TM domain. 
Late membrane permeabilization may be carried out by viroporins or by the TM domains 











Figure 4: Chemical structures of several inhibitors of viroporin activity. 
 
